Newswire (Published: Monday, February 6, 2017, Received: Thursday, February 2, 2017, 12:43:21 PM CST)
Word Count: 498
Research Conducted at University of Wisconsin Has Provided New Information about Prostate Cancer (The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma)
By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Current study results on Oncology - Prostate Cancer have been published. According to news reporting originating from Madison, Wisconsin, by NewsRx correspondents, research stated, "Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being investigated in late-stage clinical trials for the management of advanced prostate cancer."
Our news editors obtained a quote from the research from the University of Wisconsin, "Therefore, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel, including physicians, nurses, and patient advocates, to develop consensus recommendations for the clinical application of immunotherapy for prostate cancer patients. To do so, a systematic literature search was performed to identify high-impact papers from 2006 until 2014 and was further supplemented with literature provided by the panel. Results from the consensus panel voting and discussion as well as the literature review were used to rate supporting evidence and generate recommendations for the use of immunotherapy in prostate cancer patients. Sipuleucel-T, an autologous dendritic cell vaccine, is the first and currently only immunotherapeutic agent approved for the clinical management of metastatic castrate resistant prostate cancer (mCRPC). The consensus panel utilized this model to discuss immunotherapy in the treatment of prostate cancer, issues related to patient selection, monitoring of patients during and post treatment, and sequence/combination with other anti-cancer treatments. Potential immunotherapies emerging from late-stage clinical trials are also discussed."
According to the news editors, the research concluded: "As immunotherapy evolves as a therapeutic option for the treatment of prostate cancer, these recommendations will be updated accordingly."
For more information on this research see: The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. Journal for Immunotherapy of Cancer, 2016;4():92 (see also Oncology - Prostate Cancer).
The news editors report that additional information may be obtained by contacting D.G. McNeel, University of Wisconsin Carbone Cancer Center, 7007 WIMR, 1111 Highland Avenue, Madison, WI 53705, United States. Additional authors for this research include N.H. Bander, T.M. Beer, C.G. Drake, L. Fong, S. Harrelson, P.W. Kantoff, R.A. Madan, W.K. Oh, D.J. Peace, D.P. Petrylak, H. Porterfield, O. Sartor, N.D. Shore, S.F. Slovin, M.N. Stein, J. Vieweg and J.L Gulley.
Keywords for this news article include: Madison, Oncology, Wisconsin, Carcinomas, Immunology, Men's Health, United States, Immunotherapy, Prostate Cancer, Clinical Research, Drugs and Therapies, Prostatic Neoplasms, North and Central America, Clinical Trials and Studies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Medical Specialties and Practices
Treatments and Therapies